Waycross Partners’s Pfizer PFE Stock Holding History

Waycross Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,245	Closed	-$214K	–	98
2023 Q1	$214K	Sell	5,245 -5,000	-49%	-$216K	0.06%	87
2022 Q4	$525K	Hold	10,245	–	–	0.19%	71
2022 Q3	$448K	Hold	10,245	–	–	0.3%	75
2022 Q2	$537K	Hold	10,245	–	–	0.36%	66
2022 Q1	$530K	Hold	10,245	–	–	0.31%	69
2021 Q4	$605K	Hold	10,245	–	–	0.35%	69
2021 Q3	$441K	Sell	10,245 -2,500	-20%	-$111K	0.28%	79
2021 Q2	$499K	Hold	12,745	–	–	0.27%	67
2021 Q1	$462K	Hold	12,745	–	–	0.26%	73
2020 Q4	$469K	Buy	+12,745	New	+$467K	0.29%	69

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Waycross Partners's PFE Position: Q2 2023 in Review

Waycross Partners sold out of Pfizer (PFE) in Q2 2023, closing a stake of 5,245 shares — an estimated $214K sold.

Waycross Partners first reported a position in PFE in Q4 2020 and held it in 10 quarters. The position peaked at $605K in Q4 2021. 3,041 funds tracked by Wall St. Rank hold PFE as of Q2 2023.

Waycross Partners reported no remaining Pfizer position as of Q2 2023 after selling out during the quarter.
Waycross Partners sold 5,245 Pfizer shares in Q2 2023, an estimated $214K.
Waycross Partners first reported a position in Pfizer in Q4 2020 and held it in 10 quarters.
Waycross Partners's Pfizer position peaked at $605K in Q4 2021.
3,041 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.

Based on Waycross Partners's 13F filing for Q2 2023, filed 26 Jul 2023.